Fig. 5.

Comparison of seizure protection time course between riluzole and 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19). (a) Time course of seizure protection in the mouse maximal electroshock (MES) test following intraperitoneal (i.p.) administration of riluzole as a solution (n = 8 per time point). (b) Dose–response curves for seizure protection in MES test (□) and neurological impairment (■) following i.p. administration of increasing riluzole doses in mice (n = 8 per dose, 10-min time point). ED₅₀ 5.37 mg/kg [95 % confidence interval (CI) 5.17–5.57], TD₅₀ 15.77 mg/kg (95 % CI 11.94–20.83); protective index (PI) 2.9. (c) Time course of seizure protection in the mouse MES test following i.p. administration of SKA-19 as a solution (n = 6–8 per time point). (d) Dose–response curves for seizure protection in MES test (□) and neurological impairment (■) following i.p. administration of increasing SKA-19 doses in mice (n = 6–8 per dose, 10-min time point). ED₅₀ 4.93 mg/kg (95 % CI 4.15–5.86), TD₅₀ 16.08 mg/kg (95 % CI 13.06–19.02); PI 3.2